AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
Log in

NASDAQ:MNOVMediciNova Stock Price, Forecast & News

$5.44
-0.13 (-2.33 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.38
Now: $5.44
$5.60
50-Day Range
$4.97
MA: $5.49
$7.06
52-Week Range
$2.79
Now: $5.44
$10.84
Volume67,131 shs
Average Volume141,211 shs
Market Capitalization$239.73 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Read More
MediciNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Employees9
Market Cap$239.73 million
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

How has MediciNova's stock been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MNOV shares have increased by 65.3% and is now trading at $5.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MediciNova.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for MediciNova.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, April, 23rd. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.02. View MediciNova's earnings history.

What price target have analysts set for MNOV?

1 equities research analysts have issued 1-year price targets for MediciNova's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate MediciNova's share price to reach $11.00 in the next year. This suggests a possible upside of 102.2% from the stock's current price. View analysts' price targets for MediciNova.

Has MediciNova been receiving favorable news coverage?

Press coverage about MNOV stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MediciNova earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMediciNova.

Are investors shorting MediciNova?

MediciNova saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,260,000 shares, a drop of 6.2% from the April 30th total of 2,410,000 shares. Based on an average trading volume of 180,800 shares, the short-interest ratio is currently 12.5 days. Currently, 6.1% of the company's shares are sold short. View MediciNova's Current Options Chain.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.42%), Essex Woodlands Management Inc. (2.51%), State Street Corp (1.69%), Geode Capital Management LLC (1.28%), Morgan Stanley (0.52%) and Alps Advisors Inc. (0.18%). Company insiders that own MediciNova stock include Kazuko Matsuda and Yuichi Iwaki. View institutional ownership trends for MediciNova.

Which institutional investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, State Street Corp, Essex Woodlands Management Inc., Alps Advisors Inc., BlackRock Inc., and Deutsche Bank AG. View insider buying and selling activity for MediciNova.

Which institutional investors are buying MediciNova stock?

MNOV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Geode Capital Management LLC, JPMorgan Chase & Co., SG Americas Securities LLC, BNP Paribas Arbitrage SA, Jane Street Group LLC, and Citigroup Inc.. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki. View insider buying and selling activity for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $5.44.

How big of a company is MediciNova?

MediciNova has a market capitalization of $239.73 million. MediciNova employs 9 workers across the globe.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.